株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

内耳疾患:新しい薬物送達アプローチ

Inner Ear Diseases: Novel Drug Delivery Approaches

発行 ROOTS ANALYSIS 商品コード 318047
出版日 ページ情報 英文 179 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: ROOTS ANALYSIS社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
内耳疾患:新しい薬物送達アプローチ Inner Ear Diseases: Novel Drug Delivery Approaches
出版日: 2014年11月05日 ページ情報: 英文 179 Pages
概要

さまざまな内耳疾患に対し、各種投与経路(直接・間接)による40種以上の薬剤が現在臨床試験の段階にあり、関連の事業者は、この市場の秘める可能性を認識しつつあります。特に内耳に直接投与する薬剤は徐放性を持っており、薬剤全体の有効性を高めています。現在のところ上市済みの薬剤はありませんが、開発活動は活発であり、パイプラインのさまざまな段階に20を超える分子候補があります。内耳への直接投与薬の上市の第一弾は2017年になると予測されており、その後の2017年から2025年にかけて、市場は96.7%のCAGRで好調に推移すると予測されています。

当レポートでは、さまざまな投与経路による内耳疾患治療薬の開発動向について調査し、

第1章 序文

第2章 エグゼクティブサマリー

第3章 内耳:

  • 概要
  • 耳の構造
    • 外耳
      • 耳介
      • 耳道
      • 鼓膜
    • 中耳
    • 内耳
      • 三半規管
      • 内耳腔
      • 蝸牛
  • 内耳疾患
    • メニエール病
    • 感音性難聴
    • 内耳炎
    • 自己免疫性内耳疾患(AIED)
    • 前庭神経炎
    • 良性発作性頭位めまい(BPPV)
    • 耳鳴
    • 聴器毒性
    • 騒音性難聴
  • 内耳への薬物送達
    • 全身性薬物送達
    • 中耳内の薬物送達
    • 蝸牛内への薬物送達
  • インプラントのタイプ
    • 蝸牛インプラント
    • その他のインプラント

第4章 内耳薬物送達:パイプライン分析

  • 概要
  • 企業主導の内耳疾患用薬剤
    • 開発段階による分布
    • 適応症による分布
    • 薬剤の性質による分布
    • 投与経路による分布
  • 内耳疾患に関する学術研究
    • 内耳疾患用薬剤
    • 内耳疾患のためのナノ粒子
    • 内耳疾患のための遺伝子治療/幹細胞
  • 現在の治療レジメン
    • 耳鳴
    • メニエール病
    • 感音性難聴

第5章 内耳への直接的な薬物送達:中耳内、蝸牛内、経鼓膜、経迷路による薬物送達

  • 概要
  • 現在のパイプライン
    • 開発後期段階の2種の薬剤
  • 薬剤の特性
  • 標的適応症
  • 送達経路
  • 売上予測
    • 予測範囲・手法
    • 全体の市場規模・予測
  • 薬剤プロファイル
    • AM-101, Auris Medical Holding AG
    • AM-111, Auris Medical Holding AG
    • Latanoprost, Synphora AB
    • OTO-104, Otonomy
    • CGF166, Novartis and GenVec
      • 製品の仕様
      • 開発の経緯と現状
      • 臨床試験の結果
      • 売上予測、など
  • Roots Analysisによる展望分析

第6章 ケーススタディ

  • イントロダクション
    • Orbis Biosciences
    • Autifony Therapeutics
    • AudioCure
    • Sensorion Pharma

第7章 蝸牛インプラント(人工内耳)

  • イントロダクション
    • 蝸牛インプラントの歴史
    • 蝸牛インプラントの働き
    • 蝸牛インプラントのための候補
  • 現在の市場情勢
    • 蝸牛インプラントの比較分析
  • 売上予測
    • 予測手法
    • 全体の市場規模と予測
  • 主要企業プロファイル
    • Cochlear Limited
    • Med-El
    • Advanced Bionics (Sonova Holding Agが買収)
    • Neurelec SA (William Demant Holdingが買収)
    • Hangzhou Nurotron Biotechnology
      • 製品ポートフォリオ
      • パートナーシップ
      • 製造設備
      • 将来の展望、など
  • 競合情勢
  • Roots Analysisによる展望分析

第8章 インタビュー

  • Hans Rommelspacher氏(CEO, AudioCure Pharma)
  • Laurent Nguyen博士(CEO, Sensorion Pharma)
  • Maria Flynn氏(President and CEO& Nathan Dormer, Director of Formulation Sciences, Orbis Biosciences)
  • Barbara Domayne-Hayman氏(Chief Business Officer, Autifony Therapeutics)

第9章 総論

  • 耳の適応症:市場成長のための推進因子
  • 鼓室内および蝸牛内の薬物送達:将来重要な役割を果たす
  • 進化を続ける市場情勢
  • 新興技術
  • 直接的な内耳薬物送達:10年以内に10億ドル規模と市場機会は大きい

付録

図表

目次
Product Code: RA10025

A significant proportion of the world's population is suffering from otologic diseases. Absence of any disease modifying drugs is a big unmet need in the market. The current treatment of inner ear diseases is primarily based on counselling, electric and magnetic nerve stimulations. At the same time, there is a growing off-label use of drugs for symptomatic relief. Cochlear implants, brainstem implants and hearing aids are other commonly available options to the patients to overcome hearing damages. However, these options do suffer from several limitations such as high cost, poor sound quality, and painful surgeries (in case of implants). The widening gap between the demand and supply of drugs is likely to provide a major impetus to the market in the coming decade. The drugs for direct delivery to inner ear are currently under development and, once approved, are likely to gain a major share of the market.

Direct drug delivery to the inner ear is difficult due to the complex labyrinthine structure of the ear. However, with growing advances in technology and the increasing demands for specific drugs, direct inner ear drug delivery has become one of the key focus areas of researchers and companies across the world. The industry and university sponsored research is aimed at improving the current treatment regime and increasing the concentration of the drug in the inner ear for a promising treatment of otologic diseases. Specifically, intratympanic and intracochlear drug delivery routes are being explored by several stakeholders to devise efficient drug delivery strategies.

Cochlear implants (the only robust option currently available for permanent hearing loss) have also garnered increased attention worldwide. There are currently four established players: Cochlear Ltd., MED-EL, Advanced Bionics and Neurelec. However, the market is gradually opening up and newer players such as China‘s Hangzhou Nurotron have made efforts to come up with cost efficient implants. In addition, the industry has witnessed significant technological advancements with the introduction of water proof speech processors, prolonged battery life and compatibility with remote assistant. ‘Bio-Active' drug eluting cochlear implants are also anticipatedto be available in the market in the near future.

Synopsis:

The ‘Inner Ear Diseases: Novel Drug Delivery Approaches, 2014 - 2025’ report provides an extensive study of the emerging market of drugs and cochlear implants for otologic diseases. The focus of this study is primarily on the drugs targeting inner ear diseases delivered through intratympanic and intracochlear routes; these drugs provide improved retention time, increase patient compliance, lower treatment cost and offer numerous other advantages. The report covers various aspects such as research pipeline (both industry and academia), technological improvements, sales potential and competitive landscape to assess new evolving opportunities. The study also identifies cochlear implants which are currently available in the market. We have provided a competitive spider web analysis to compare the various implants based on technical parameters (electrode length, electrode contact points etc.) and their user friendliness.

One of the key objectives of this report is to understand the current and future state of the recent advances in drugs and devices for inner ear diseases market. This is done by analyzing the following:

  • Drugs for inner ear delivery currently in the pipeline
  • Size of target consumer segments
  • Frequency of drug injections per year
  • Variable price points
  • Surgical intervention rates

In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The base year for the report is 2014. The report provides market forecasts for the period 2014 - 2025. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. More than 40 drugs are in clinical trials for various inner ear diseases through different routes of administration (both direct and indirect); the companies have now started to realize the potential of this market.
  • 2. Specifically, drugs delivered directly to the inner ear offer sustained release of the drug increasing the overall efficacy. Currently, there are no marketed drugs yet; however, the pipeline is rich with over 20 molecules in various stages of development.
  • 3. The first batch of drugs for direct inner ear delivery are anticipated to be launched in 2017; post this, we expect the market to grow at a healthy annualized rate of 96.7% during 2017 - 2025.
  • 4. Auris Medical is the key leading player, with two of its drugs (AM-101 and AM-111) in late stage clinical trial studies. Other examples include Synphora AB, Orbis Biosciences, O-Ray Pharma, Quark Pharma, Otonomy and Sound Pharmaceuticals. Overall, we have identified 12 companies working in this area.
  • 5. With regards to the cochlear implants, the market is extremely consolidated; in 2013, Cochlear Ltd. captured over 50% of the total market (in terms of number of units sold). We expect the overall market to grow at an annualized rate of 7.49% from 2014-2025.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high level view on the current scenario of the market of inner ear drugs and devices and the likely mid-long term evolution.

Chapter 3 provides a general overview of inner ear diseases such as tinnitus, sensorineural hearing loss, meniere's disease, drug induced ototoxicity etc. This section also provides an introduction to the implants (middle ear implants, cochlear implants, brainstem implants) currently available in the market. We have also discussed the various routes of administration of the drug to the inner ear; this includes systemic, intratympanic and intracochlear routes of drug delivery.

Chapter 4 offers an extensive pipeline of all the inner ear drugs that are being developed by a number of companies and academic institutions. We have also covered details of the current treatment regime for various inner ear diseases such as tinnitus, meniere's diseases and sensorineural hearing loss.

Chapter 5 covers the drugs which are under development for direct inner ear delivery. The pipeline analysis includes information on the phase of development, nature of drugs, targeted indications etc. The chapter also includes detailed profiles of drugs which are currently in clinical trials; covering information on underlying technology, development history, principal features, current status of development and likely future sales potential.

Chapter 6 provides case studies on four affiliated companies (Orbis Biosciences, Autifony Therapeutics, AudioCure and Sensorion Pharmaceuticals) outlining their current focus and unique technology / platform features.

Chapter 7 focuses on cochlear implants. We have included detailed company profiles of the manufacturers of these implants. These profiles cover the company's product portfolio, financial information, sales of cochlear implants (wherever available), relevant partnerships, manufacturing facilities and respective future outlooks. We have also provided a sales forecast of cochlear implants over the next ten years.

Chapter 8 is a collection of transcripts based on our discussion with some of the upcoming players in the industry such as AudioCure, Orbis Biosciences, Autifony Therapeutics and Sensorion Pharmaceuticals.

Chapter 9 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and a brief description of some of the emerging technologies that are expected to invade the market in future.

Chapters 10 and 11 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INNER EAR: AN INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Structure of the Ear
    • 3.2.1. Outer Ear
      • 3.2.1.1. Auricle
      • 3.2.1.2. Ear Canal
      • 3.2.1.3. Tympanic Membrane
    • 3.2.2. Middle Ear
    • 3.2.3. Inner Ear
      • 3.2.3.1. Semicircular Canal
      • 3.2.3.2. Vestibule
      • 3.2.3.3. Cochlea
  • 3.3. Inner Ear Diseases
    • 3.3.1. Meniere's Disease
    • 3.3.2. Sensorineural Hearing Loss
    • 3.3.3. Labyrinthitis
    • 3.3.4. Auto-Immune Inner Ear Disease (AIED)
    • 3.3.5. Vestibular Neuritis
    • 3.3.6. Benign Paroxysmal Positional Vertigo (BPPV)
    • 3.3.7. Tinnitus
    • 3.3.8. Ototoxicity
    • 3.3.9. Noise-Induced Hearing Loss
  • 3.4. Inner Ear Drug Delivery
    • 3.4.1. Systemic Drug Delivery
    • 3.4.2. Intratympanic Drug Delivery
    • 3.4.3. Intracochlear Drug Delivery
  • 3.5. Types of Implants
    • 3.5.1. Cochlear Implants
    • 3.5.2. Other Implants

4. INNER EAR DRUG DELIVERY: PIPELINE ANALYSIS

  • 4.1. Chapter Overview
  • 4.2. Industry Sponsored Drugs for Inner Ear Diseases
    • 4.2.1. Drugs for Inner Ear Diseases: Distribution by Phase of Development
    • 4.2.2. Drugs for Inner Ear Diseases: Distribution by Indication
    • 4.2.3. Drugs for Inner Ear Diseases: Distribution by Nature of Drug
    • 4.2.4. Drugs for Inner Ear Diseases: Distribution by Route of Administration
  • 4.3. Academic Research on Inner Ear Diseases
    • 4.3.1. Drugs for Inner Ear Diseases
    • 4.3.2. Nanoparticles for Inner Ear Diseases
    • 4.3.3. Gene Therapy/ Stem Cells for Inner Ear Diseases
  • 4.4. Current Treatment Regimen
    • 4.4.1. Tinnitus
    • 4.4.2. Meniere's Disease
    • 4.4.3. Sensorineural Hearing Loss

5. DIRECT DRUG DELIVERY TO INNER EAR: INTRATYMPANIC, INTRACOCHLEAR, TRANSTYMPANIC AND INTRALABYRINTHINE ROUTES OF DELIVERY

  • 5.1. Chapter Overview
  • 5.2. Direct Drug Delivery to Inner Ear: Current Pipeline
    • 5.2.1. Two Drugs in Late Stage Development
  • 5.3. Direct Drug Delivery to Inner Ear: Nature of Drugs
  • 5.4. Direct Drug Delivery to Inner Ear: Targeted Indications
  • 5.5. Direct Drug Delivery to Inner Ear: Route of Delivery
  • 5.6. Direct Drug Delivery to Inner Ear: Sales Forecast, 2014 - 2025
    • 5.6.1. Scope and Forecast Methodology
    • 5.6.2. Overall Market Size and Forecast
  • 5.7. Drug Profiles
    • 5.7.1. AM-101, Auris Medical Holding AG
      • 5.7.1.1. Product Specifications
      • 5.7.1.2. History of Development
      • 5.7.1.3. Current Status of Development
        • 5.7.1.3.1. Post Acute Tinnitus
        • 5.7.1.3.2. Acute Tinnitus
      • 5.7.1.4. Phase II Clinical Trial Results
      • 5.7.1.5. Sales Forecast 2014-2025
    • 5.7.2. AM-111, Auris Medical Holding AG
      • 5.7.2.1. Product Specifications
      • 5.7.2.2. History of Development
      • 5.7.2.3. Current Status of Development
      • 5.7.2.4. Phase II Clinical Trial Results
      • 5.7.2.5. Sales Forecast, 2014-2025
    • 5.7.3. Latanoprost, Synphora AB
      • 5.7.3.1. Product Specifications
      • 5.7.3.2. Current Status of Development
      • 5.7.3.3. Phase II Clinical Trial Results
      • 5.7.3.4. Sales Forecast, 2014-2025
    • 5.7.4. OTO-104, Otonomy
      • 5.7.4.1. Product Specifications
      • 5.7.4.2. History and Current Status of Development
      • 5.7.4.3. Phase II Clinical Trial Results
      • 5.7.4.4. Sales Forecast, 2014-2025
    • 5.7.5. CGF166, Novartis and GenVec
      • 5.7.5.1. Product Specifications
      • 5.7.5.2. History and Current Status of Development
      • 5.7.5.3. Preclinical Trial Results
      • 5.7.5.4. Sales Forecast, 2014-2025
  • 5.8. Direct Drug Delivery to Inner Ear: Roots Analysis' Perspective

6. CASE STUDIES

  • 6.1. Introduction
    • 6.1.1. Orbis Biosciences
    • 6.1.2. Autifony Therapeutics
    • 6.1.3. AudioCure
    • 6.1.4. Sensorion Pharma

7. COCHLEAR IMPLANTS (BIONIC EARS)

  • 7.1. Introduction
    • 7.1.1. History of Cochlear Implants
    • 7.1.2. Working of a Cochlear Implant
    • 7.1.3. Candidacy for a Cochlear Implant
  • 7.2. Cochlear Implants: Current Market Landscape
    • 7.2.1. Comparative Analysis of Cochlear Implants
  • 7.3. Cochlear Implants: Sales Forecast, 2014-2025
    • 7.3.1. Forecast Methodology
    • 7.3.2. Overall Market Size and Forecast
  • 7.4. Key Company Profiles
    • 7.4.1. Cochlear Limited
      • 7.4.1.1. Financial Information
      • 7.4.1.2. Cochlear Implants: Historical Sales
      • 7.4.1.3. Product Portfolio: Nucleus 5, 6, Hybrid and Other Implant Systems
      • 7.4.1.4. Partnerships
      • 7.4.1.5. Manufacturing Facility
      • 7.4.1.6. Future Outlook
    • 7.4.2. Med-El
      • 7.4.2.1. Product Portfolio: EAS, Maestro, Synchrony and Other Implant Systems
      • 7.4.2.2. Partnerships
      • 7.4.2.3. Manufacturing Facilities
      • 7.4.2.4. Future Outlook
    • 7.4.3. Advanced Bionics (Acquired by Sonova Holding Ag)
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Information
      • 7.4.3.3. Product Portfolio: HiRes90K and HiRes90K Advantage
      • 7.4.3.4. Partnerships
      • 7.4.3.5. Manufacturing Facilities
      • 7.4.3.6. Future Outlook
    • 7.4.4. Neurelec SA (Acquired by William Demant Holding)
      • 7.4.4.1. Financial Information
      • 7.4.4.2. Product Portfolio: Digisonic SP and Digisonic SP Binaural
      • 7.4.4.3. Other Products
      • 7.4.4.4. Partnerships
      • 7.4.4.5. Future Outlook
    • 7.4.5. Hangzhou Nurotron Biotechnology
      • 7.4.5.1. Product Portfolio
      • 7.4.5.2. Partnerships
      • 7.4.5.3. Manufacturing Facilities
      • 7.4.5.4. Future Outlook
  • 7.5. Competitive Landscape
  • 7.6. Cochlear Implants: Roots Analysis' Perspective

8. INTERVIEW TRANSCRIPTS

  • 8.1. Prof. Hans Rommelspacher, CEO, AudioCure Pharma
  • 8.2. Dr. Laurent Nguyen, CEO, Sensorion Pharma
  • 8.3. Maria Flynn, President and CEO& Nathan Dormer, Director of Formulation Sciences, Orbis Biosciences
  • 8.4. Barbara Domayne-Hayman, Chief Business Officer, Autifony Therapeutics

9. CONCLUSION

  • 9.1. Otologic Indications: Drivers for Market Growth
  • 9.2. Intratympanic and Intracochlear Drug Delivery to Play A Key Role in the Future
  • 9.3. Market Landscape will Continue to Evolve
  • 9.4. Emerging Technologies
  • 9.5. Direct Inner Ear Drug Delivery: Overall Opportunity is Big; A Billion Dollar Market Within a Decade

10. APPENDIX 1: TABULATED DATA

11. APPENDIX 2: LIST OF COMPANIES

List of Figures:

  • Figure 4.1 Industry Sponsored Inner Ear Drugs: Distribution by Phase of Development
  • Figure 4.2: Industry Sponsored Inner Ear Drugs: Distribution by Target Indication
  • Figure 4.3: Industry Sponsored Inner Ear Drugs: Distribution by Nature of Drug
  • Figure 4.4: Industry Sponsored Inner Ear Drugs: Distribution by Route of Administration
  • Figure 4.5: Academia Sponsored Inner Ear Drugs: Distribution by Route of Administration
  • Figure 4.6: Academia Sponsored Inner Ear Drugs: Distribution by Target Indication
  • Figure 5.1: Inner Ear Drug Developers: Number of Drugs Under Development
  • Figure 5.2: Drugs Directly Delivered Into Inner Ear: Distribution by Phase of Development
  • Figure 5.3: Drugs Directly Delivered Into Inner Ear: Distribution by Nature of Active Substance
  • Figure 5.4: Drugs Directly Delivered Into Inner Ear: Distribution by Type of Indication
  • Figure 5.5: Drugs Directly Delivered Into Inner Ear: Distribution by Route of Administration
  • Figure 5.6: Inner Ear Direct Drug Delivery Market Forecast, 2014 - 2025: Base Scenario (USD Million)
  • Figure 5.7: AM-101: Development History
  • Figure 5.8: AM-101: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
  • Figure 5.9: AM-111: Development History
  • Figure 5.10: AM-111: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
  • Figure 5.11: Latanoprost: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
  • Figure 5.12: OTO-104: Development History
  • Figure 5.13: OTO-104: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
  • Figure 5.14: CGF166: Development History
  • Figure 5.15: CGF166: Sales Forecast, 2014 - 2025: Base Scenario (USD Million)
  • Figure 5.16: Drug Directly Delivered Into Inner Ear: Drivers and Restraints
  • Figure 7.1: Cochlear Implants: Development History
  • Figure 7.2: Working of a Cochlear Implant
  • Figure 7.3: Cochlear Implants: Distribution by Year of Development
  • Figure 7.4: Cochlear Implants: Comparative Analysis
  • Figure 7.5: Cochlear Implants: Sales Forecast, 2014 - 2025: Base Scenario (USD Billion)
  • Figure 7.6: Cochlear Implant Manufacturers: Distribution by Market Share
  • Figure 7.7: Cochlear Ltd Annual Revenues, 2010-2014 (USD Million)
  • Figure 7.8: Cochlear Ltd Annual Revenues, 2014: Distribution by Products (USD Million)
  • Figure 7.9: Cochlear Ltd Annual Revenues: Distribution by Regions (USD Million)
  • Figure 7.10: Cochlear Ltd: Units of Implants Sold, 2010-2014
  • Figure 7.11: Number of Cochlear Ltd Implants Implanted Till 2014
  • Figure 7.12: Nucleus 5 Cochlear Implant: Internal and External Components
  • Figure 7.13: Sonova Holding Annual Revenues, 2009-2013 (CHF Million)
  • Figure 7.14: Sonova Holding Annual Revenues, 2013: Distribution by Products (CHF Million)
  • Figure 7.15: Sonova Holding Cochlear Implant Revenues, 2010-2013 (CHF Million)
  • Figure 7.16: Sonova Holding Revenues, 2013: Distribution by Operating Regions (CHF Million)
  • Figure 7.17: William Demant Annual Revenues, 2009-2013 (DKK Million)
  • Figure 7.18: William Demant Annual Revenues: Distribution by Products, 2013 (DKK Million)
  • Figure 7.19: Cochlear Implants Market: Drivers and Restraints
  • Figure 9.1: Direct Inner Ear Drug Delivery Market, 2017, 2021, 2025 (USD Million)

List of Tables:

  • Table 3.1: Middle Ear: Auditory Ossicles
  • Table 3.2: Examples of Outer, Middle and Inner Ear Diseases
  • Table 3.3: Inner Ear Drug Delivery Methods
  • Table 4.1: Drugs for Inner Ear Diseases: Clinical / Preclinical Pipeline
  • Table 4.2: Drugs for Inner Ear Diseases: Research Pipeline at Universities
  • Table 4.3: Nanoparticles for Inner Ear Diseases: Research Pipeline at Universities
  • Table 4.4: Gene Therapies/ Stem Cells for Inner Ear Diseases: Research Pipeline at Universities
  • Table 5.1: Drugs Directly Delivered Into Inner Ear: Clinical / Pre-clinical Pipeline
  • Table 5.2: Current Development Phase and Expected Launch Year of Drugs in Clinical Development
  • Table 5.3: AM-101: Ongoing Phase III Clinical Trials
  • Table 5.4: AM-111: Completed/ Planned Clinical Trials
  • Table 5.5: CGF166: Patent Portfolio
  • Table 5.6: CGF166: Preclinical Trial Studies
  • Table 6.1: Case Study: Molecules and their Target Indication
  • Table 7.1: Degree of Hearing Loss
  • Table 7.2: Cochlear Implants: Comparative Analysis
  • Table 7.3: Cochlear Ltd: Marketed Cochlear Implants
  • Table 7.4: MED-EL: Marketed Cochlear Implant Systems
  • Table 7.5: MED-EL: Marketed Cochlear Implants
  • Table 7.6: Advanced Bionics: Product Portfolio
  • Table 7.7: HiRes 90K: Technical Specifications
  • Table 7.8: Digisonic SP and Digisonic SP Binaural: Technical Specifications
  • Table 7.9: Competitive Landscape: Implants and Devices
  • Table 7.10: Models of Hearing Aids
  • Table 7.11: Hearing Products: Competitive Analysis
  • Table 10.1: Industry Sponsored Inner Ear Drugs: Distribution by Phase of Development
  • Table 10.2: Industry Sponsored Inner Ear Drugs: Distribution by Target Indication
  • Table 10.3: Industry Sponsored Inner Ear Drugs: Distribution by Nature of Drug
  • Table 10.4: Industry Sponsored Inner Ear Drugs: Distribution by Route of Administration
  • Table 10.5: Industry Sponsored Inner Ear Drugs: Distribution by Routes of Delivery
  • Table 10.6: Academic Research Sponsored Inner Ear Drugs: Distribution by Route of Administration
  • Table 10.7: Academic Research Sponsored Inner Ear Drugs: Distribution by Target Indication
  • Table 10.8: Inner Ear Drug Developers: Number of Drugs Under Development
  • Table 10.9: Drugs Directly Delivered Into Inner Ear: Distribution by Phase of Development
  • Table 10.10: Drugs Directly Delivered Into Inner Ear: Distribution by Nature of Active Substance
  • Table 10.11: Drugs Directly Delivered Into Inner Ear: Distribution by Type of Indication
  • Table 10.12: Drugs Directly Delivered Into Inner Ear: Distribution by Route of Administration
  • Table 10.13: Inner Ear Direct Drug Delivery: Sales Forecast, 2014 - 2025, Base Scenario (USD Million)
  • Table 10.14: Inner Ear Direct Drug Delivery: Sales Forecast, 2014 - 2025, Conservative Scenario (USD Million)
  • Table 10.15: Inner Ear Direct Drug Delivery: Sales Forecast, 2014 - 2025, Optimistic Scenario (USD Million)
  • Table 10.16: AM-101: Sales Forecast, 2014 - 2025, Base Scenario (USD Million)
  • Table 10.17: AM-101: Sales Forecast, 2014 - 2025, Conservative Scenario (USD Million)
  • Table 10.18: AM-101: Sales Forecast, 2014 - 2025, Optimistic Scenario (USD Million)
  • Table 10.19: AM-111: Sales Forecast, 2014 - 2025, Base Scenario (USD Million)
  • Table 10.20: AM-111: Sales Forecast, 2014 - 2025, Conservative Scenario (USD Million)
  • Table 10.21: AM-111: Sales Forecast, 2014 - 2025, Optimistic Scenario (USD Million)
  • Table 10.22: Latanoprost: Sales Forecast, 2014 - 2025, Base Scenario (USD Million)
  • Table 10.23: Latanoprost: Sales Forecast, 2014 - 2025, Conservative Scenario (USD Million)
  • Table 10.24: Latanoprost: Sales Forecast, 2014 - 2025, Optimistic Scenario (USD Million)
  • Table 10.25: OTO-104: Sales Forecast, 2014 - 2025, Base Scenario (USD Million)
  • Table 10.26: OTO-104: Sales Forecast, 2014 - 2025, Conservative Scenario (USD Million)
  • Table 10.27: OTO-104: Sales Forecast, 2014 - 2025, Optimistic Scenario (USD Million)
  • Table 10.28: CGF166: Sales Forecast, 2014 - 2025, Base Scenario (USD Million)
  • Table 10.29: CGF166: Sales Forecast, 2014 - 2025, Conservative Scenario (USD Million)
  • Table 10.30: CGF166: Sales Forecast, 2014 - 2025, Optimistic Scenario (USD Million)
  • Table 10.31: Cochlear Implants: Sales Forecast, 2014 - 2025, Base Scenario (USD Billion)
  • Table 10.32: Cochlear Implants: Sales Forecast, 2014 - 2025, Conservative Scenario (USD Billion)
  • Table 10.33: Cochlear Implants: Sales Forecast, 2014 - 2025, Optimistic Scenario (USD Billion)
  • Table 10.34: Cochlear Implant Manufacturers: Distribution by Market Share
  • Table 10.35: Cochlear Ltd Annual Revenues, 2010-2014 (USD Million)
  • Table 10.36: Cochlear Ltd Annual Revenues, 2014: Distribution by Products (USD Million)
  • Table 10.37: Cochlear Ltd Annual Revenues: Distribution by Regions (USD Million)
  • Table 10.38: Cochlear Ltd: Units of Implants Sold, 2010-2014 (USD Million)
  • Table 10.39: Number of Cochlear Ltd Implants Implanted Till 2014
  • Table 10.40: Sonova Holding Annual Revenues, 2009-2013 (CHF Million)
  • Table 10.41: Sonova Holding Annual Revenues, 2013: Distribution by Products (CHF Million)
  • Table 10.42: Sonova Holding Cochlear Implant Revenues, 2010-2013 (CHF Million)
  • Table 10.43: Sonova Holding Cochlear Implant Revenues, 2013: Distribution by Operating Regions (CHF Million)
  • Table 10.44: William Demant Annual Revenues, 2009-2013 (DKK Million)
  • Table 10.45: William Demant Annual Revenues: Distribution by Products, 2013 (DKK Million)
  • Table 10.46: Direct Inner Ear Drug Delivery Market, 2017, 2021, 2025 (USD Million)

List of Companies:

The following companies and organizations have been mentioned in the report.

  • 1. Acousia Therapeutics
  • 2. Advanced Bionics
  • 3. Akloma Bioscience AB
  • 4. America Tinnitus Association
  • 5. Atlassian
  • 6. Audibel
  • 7. Audina
  • 8. Audio Controle
  • 9. AudioCure Pharma
  • 10. Audion Therapeutics
  • 11. Auris Medical
  • 12. Autifony Therapeutics
  • 13. Beltone
  • 14. Bionic Ear Institute
  • 15. Brainsway
  • 16. Cerbomed
  • 17. Carl Zeiss NTS GmbH
  • 18. CharlesdeGiorgio
  • 19. Chungbuk National University
  • 20. Cochlear Ltd.
  • 21. College of Medicine, Seoul, Korea
  • 22. Connect Hearing
  • 23. Cornell University
  • 24. Coselgi
  • 25. Dicton
  • 26. Electone
  • 27. Eli Lilly
  • 28. Elkon
  • 29. Emory University School of Medicine
  • 30. EstimME
  • 31. Eurion
  • 32. Flexion Therapeutics
  • 33. Fudan University
  • 34. Genentech
  • 35. General Hearing Instruments
  • 36. General Pharma
  • 37. Genetic Therapeutics
  • 38. GenVec
  • 39. GN Resound
  • 40. Google
  • 41. Government Medical College, Amritsar (India)
  • 42. GSK
  • 43. Hangzhou Nurotron
  • 44. Hansaton
  • 45. Immune Pharmaceuticals
  • 46. IN4 Care
  • 47. Inception 3
  • 48. Incube labs
  • 49. Interton
  • 50. Jichi Medical University
  • 51. John Hopkins University
  • 52. Kagoshima University
  • 53. Korea Otsuka Pharmaceutical
  • 54. Kyorin Pharmaceuticals
  • 55. Kyoto University, Japan
  • 56. Laboratories Servier
  • 57. Lincoln pharma
  • 58. Macquarie University
  • 59. Masaryk University
  • 60. Mathworks
  • 61. MED-EL
  • 62. Medical University of Vienna
  • 63. MedGenesis
  • 64. Merz Pharmaceuticals
  • 65. Micro Tech Hearing Instruments
  • 66. Microtransponder
  • 67. Miracle-Ear
  • 68. National University Boramae Medical Centre
  • 69. Naval Medical Center San Diego
  • 70. Neurelec
  • 71. Neurotherapies Reset
  • 72. New York Eye and Ear Infirmary
  • 73. Novartis
  • 74. NXP Semiconductors
  • 75. O-Ray Pharma
  • 76. Orbis Biosciences
  • 77. Oricula Therapeutics
  • 78. Oticon Medical
  • 79. Otologic Therapeutics
  • 80. Otonomy
  • 81. Panasonic
  • 82. Persona Medical
  • 83. Phafag
  • 84. Phonak
  • 85. Quark Pharma
  • 86. Resound
  • 87. Rexton
  • 88. Rion
  • 89. Roche
  • 90. Rudolf Magnus Institute of Neuroscience
  • 91. S3 Group
  • 92. Sebotek
  • 93. Sensorion Pharmaceuticals
  • 94. Seoul National University College of Medicine, Seoul
  • 95. Seoul National University Hospital
  • 96. Siemens
  • 97. SIU School of Medicine
  • 98. Solvay Pharmaceuticals
  • 99. Sonic Innovations
  • 100. Sonnovation
  • 101. Sonova Holding
  • 102. SophonoTron
  • 103. Sotex
  • 104. Sound Pharmaceuticals
  • 105. Southern Illinois University
  • 106. Stanford University
  • 107. Starkey
  • 108. Synphora AB
  • 109. The Catholic University of Korea
  • 110. Unitron
  • 111. Universidad de Valladolid y Consejo Superior de InvestigacionesCientíficas
  • 112. University at Buffalo
  • 113. University College of London
  • 114. University Medical Centre Utrecht
  • 115. University of Bath
  • 116. University of Bonn
  • 117. University of California San Francisco
  • 118. University of Heidelberg
  • 119. University of Innsbruck
  • 120. University of Kansas
  • 121. University of Maryland
  • 122. University of Melbourne
  • 123. University of Miami
  • 124. University of Michigan Health System
  • 125. University of Oklahoma Health Sciences Centre
  • 126. University of Pennsylvania School of Medicine
  • 127. University of Tampere
  • 128. University of Tübingen
  • 129. University of Veterinary Medicine Vienna, Austria
  • 130. Versant Ventures
  • 131. Widex
  • 132. William Demant Holding
  • 133. WiserBAN Consortium
  • 134. Xiangya Hospital of Central South University
  • 135. XOMA
Back to Top